• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human Uncharacterized protein C2orf62 (C2orf62)

ACP15429

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP15429 Target NameCATIP
FormLyophilized powderExpression SystemCustom Production. Please inquire and provide the desire expression system.
Expression Range1-387Protein LengthFull length protein
Purity>85% (SDS-PAGE)Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDQ7Z7H3
Background Information
  • Uniprot Id

    Q7Z7H3

  • Target Species

    Human

  • Target Name

    CATIP

  • Target Full Name

    Ciliogenesis-associated TTC17-interacting protein

  • Target Function

    Plays a role in primary ciliogenesis by modulating actin polymerization.

  • Target Subcellular Location

    Nucleus. Cytoplasm. Cell membrane. Cytoplasm, cytoskeleton. Note=Colocalized with TTC17 at F-actin rich zones and at dynamic plasma membrane protrusions.

  • Target Protein Families

    CATIP family

  • Target Tissue Specificity

    Strongly expressed in round and elongating spermatids, weakly in pachytene spermatocytes. Expressed in Leydig cells (at protein level). Expressed in testis, placenta, prostate and lung, and moderately in ovary and brain.

  • Target Synonyms

    C2orf62; CB062_HUMAN; Chromosome 2 open reading frame 62; Hypothetical gene supported by BC052750; Hypothetical protein LOC375307; OTTHUMP00000164138; Uncharacterized protein C2orf62; Uncharacterized protein C2orf62 homolog

Inquire Recombinant Human Uncharacterized protein C2orf62 (C2orf62) Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification